|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||180.40 - 180.40|
|52-week range||148.41 - 264.40|
|Beta (5Y monthly)||0.65|
|PE ratio (TTM)||21.68|
|Forward dividend & yield||1.97 (1.09%)|
|Ex-dividend date||25 Apr 2022|
|1y target est||N/A|
Germany's Merck KGaA on Monday said it aims to double the productivity of its research and development into oncology, neurology and immunology treatments. The company is holding an investor day on its healthcare research and development strategy on Monday.
German diversified group Merck KGaA has tapped Goldman Sachs to revive a $1 billion sale of its pigments division after previous attempts to sell the business fell through during the pandemic, three sources told Reuters. The business, known as Surface Solutions, has already drawn interest from Austrian rival Heubach, owned by SK Capital Partners, one of the sources said, speaking on condition of anonymity. Surface Solutions makes pigments for a pearlescent or metallic shine in coatings, plastics and cosmetics and could be valued at about 1 billion euros ($1.03 billion), the sources said.